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Higher resting heart rate is associated with increased cardiovascular disease and mortality risk. Though heri-
table factors play a substantial role in population variation, little is known about specific genetic determi-
nants. This knowledge can impact clinical care by identifying novel factors that influence pathologic heart
rate states, modulate heart rate through cardiac structure and function or by improving our understanding
of the physiology of heart rate regulation. To identify common genetic variants associated with heart rate,
we performed a meta-analysis of 15 genome-wide association studies (GWAS), including 38 991 subjects
of European ancestry, estimating the association between age-, sex- and body mass-adjusted RR interval
(inverse heart rate) and ∼2.5 million markers. Results with P < 5 3 1028 were considered genome-wide sig-
nificant. We constructed regression models with multiple markers to assess whether results at less stringent
thresholds were likely to be truly associated with RR interval. We identified six novel associations with rest-
ing heart rate at six loci: 6q22 near GJA1; 14q12 near MYH7; 12p12 near SOX5, c12orf67, BCAT1, LRMP and
CASC1; 6q22 near SLC35F1, PLN and c6orf204; 7q22 near SLC12A9 and UfSp1; and 11q12 near FADS1.
Associations at 6q22 400 kb away from GJA1, at 14q12 MYH6 and at 1q32 near CD34 identified in previously
published GWAS were confirmed. In aggregate, these variants explain ∼0.7% of RR interval variance. A multi-
variant regression model including 20 variants with P < 1025 increased the explained variance to 1.6%,
suggesting that some loci falling short of genome-wide significance are likely truly associated. Future
research is warranted to elucidate underlying mechanisms that may impact clinical care.
INTRODUCTION
Higher resting heart rate is associated with increased risk of
cardiovascular disease (1), cardiovascular mortality (2,3),
including sudden death (4), and all-cause mortality indepen-
dent of traditional risk factors (5–9). However, it is not
known whether heart rate directly impacts mortality or
merely reflects unrecognized subclinical disease (1,7,8).
Recently it was shown that physical exercise reduces the
increased cardiovascular mortality risk associated with
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higher heart rate (3). This suggests that heart rate is a clinically
relevant and potentially modifiable risk factor.
Heart rate is a complex trait, determined by multiple
environmental, genetic and other endogenous factors. Heredity
plays a substantial role in the inter-individual variation of
resting heart rate, accounting for 26–32% of heart rate vari-
ation in prior studies (10–13). Twin studies report even
higher heritability estimates up to 55–63% (14,15). Candidate
gene approaches have identified multiple loci associated with
heart rate (12,13,16–20), but the results have been inconsist-
ent and difficult to replicate. Genome-wide genotyping
arrays of single-nucleotide polymorphisms (SNPs) assay
common variation in the human genome and can identify
genetic variants with modest influences on a complex trait
such as heart rate, as shown by two recent genome-wide
association studies (GWAS) that identified common variation
at or near MYH6, GJA1 and CD34 associated with heart rate
(21,22). These chromosomal loci identified in an unbiased
genome-wide study may represent novel risk factors for cardi-
ovascular disease outcomes. This knowledge may also have an
impact on clinical care (i) by identifying novel factors that
cause pathologic heart rate states (such as sick sinus syndrome
or other arrhythmias), (ii) by identifying factors that influence
cardiac structure or function (e.g. stroke volume) and thereby
modulate heart rate (since cardiac output ¼ heart rate × stroke
volume) or (iii) by improving our understanding of the physio-
logic basis of heart rate regulation. Altogether this will gener-
ate insights into the underlying mechanisms of heart rate as a
well-established, but poorly understood, risk indicator for car-
diovascular disease and mortality.
To identify additional genetic determinants of heart rate, we
performed a meta-analysis of GWAS of resting heart rate,
measured as the RR interval on the electrocardiogram
(ECG) in 38 991 individuals of European ancestry derived
from 15 studies in the RRGEN consortium.
RESULTS
There were 38 991 individuals available for genotype–pheno-
type association analysis after exclusions. Subject character-
istics are shown in Table 1. While cohort-specific quantile–
quantile plots of P-value distributions approximated expec-
tations under the null, the meta-analysis of all results
showed a clear excess of low P-values (Supplementary
Material, Fig. S1). Study-specific genomic inflation lambda
values ranged from 0.98 to 1.05, suggesting that population
stratification or other technical artifacts were minimal (Sup-
plementary Material, Table S1).
Meta-analysis of results from all studies resulted in 156
SNPs reaching the pre-specified genome-wide statistical sig-
nificance level (P, 5 × 1028; Supplementary Material,
Table S2) before applying post-meta-analysis genomic
control. In total, nine independent genome-wide significant
signals were observed across seven chromosomal loci
(Table 2, Fig. 1), with all but one locus harboring multiple
SNPs reaching the genome-wide significance threshold (Sup-
plementary Material, Table S2; Fig. 2A–E).
Genome-wide significant associations were observed at 6q22
nearest to GJA1; 14q12 near MYH6 and MYH7; 12p12 near
SOX5, c12orf67, BCAT1, LRMP and CASC1; 6q22 near
SLC35F1, 6orf204 and PLN (.3 Mb away from 6q22 GJA1);
7q22 near SLC12A9; 11q12 near FADS1; and 1q32 near
CD34. The genomic inflation lambda value of the meta-analysis
was 1.05. After applying post-meta-analysis genomic control,
the signal at 1q34 near CD34 and a second independent signal
at 6q22 GJA1 lost genome-wide significance.
The strongest association was observed for an intergenic
SNP 370 kb upstream of GJA1 at 6q22 rs9398652 [minor
allele frequency (MAF) ¼ 0.10] with a 12.6 ms shorter RR
interval per minor A allele, which is equivalent to a
0.95 bpm higher heart rate based on the baseline mean heart
rate of 66.8 bpm, across all studies (P ¼ 8.0 × 10216,
Pmeta-gc ¼ 3.8 × 10215; Table 2, Fig. 2A). Cho et al. (21)
observed genome-wide significant association between
rs12110693 and pulse rate in an Asian population-based
GWAS. This SNP is in perfect linkage disequilibrium (r2 ¼
1) with rs939862 in both Caucasian and Asian HapMap refer-
ence populations and thus reflects the same signal 370 kb from
GJA1. A second SNP only 8 kb away from GJA1 also reached
genome-wide significance pre-genomic control, rs11154022
(MAF ¼ 0.33) with a 5.8 ms longer RR interval (0.43 bpm
lower heart rate) per A allele (P ¼ 3.5 × 1028, Pmeta-gc ¼
7.2 × 1028; Fig. 2B, Table 2). This SNP had low correlation
with rs9398652 (r2 ¼ 0.006 in HapMap CEU), suggesting a
novel-independent association signal. Since HapMap is
limited to 90 subjects, we assessed the linkage disequilibrium
in our data. All observed r2 values ranged between 0.0001 and
0.004, which is lower than seen in the HapMap CEU reference
population. Conditional analysis confirmed that these two
signals are independent with Pconditional ¼ 2.4 × 10211 and
Pconditional ¼ 3.3 × 1028, respectively, for rs9398652 and
rs1154022 in the subset (n ≤ 33 846) used for this analysis.
The second locus with two signals in low correlation reach-
ing genome-wide significance is located on chromosome
14q12. The strongest association at this locus was observed
for rs452036 located in intron 19 of MYH6 [MAF ¼ 0.36,
with a 7.8 ms shorter RR interval (0.58 bpm higher heart
rate) per C allele, P ¼ 8.1 × 10215, Pmeta-gc ¼ 3.8 × 10214,
Fig. 2C]. This replicates the finding by Holm et al. (22) who
previously described an association between rs452036 and
heart rate. The non-synonymous coding variant rs365990,
which results in an amino acid change at position 1101
(Alanine. Valine) of the MYH6 gene product, is a possible
functional variant since it showed strong correlation with
(r2 ¼ 0.96 in HapMap CEU) and association results are indis-
tinguishable from rs452036 (Table 2). A second SNP located
near MYH7 rs223116 (MAF ¼ 0.24), associated with a
7.4 ms shorter RR interval per A allele (0.55 bpm higher
heart rate, P ¼ 1.1 × 1028, Pmeta-gc ¼ 2.5 × 1028, Fig. 2D)
was in low correlation with rs452036 (r2 ¼ 0.08 in HapMap
CEU) and reflects a novel association. We observed r2 values
similar to HapMap CEU with values ranging from 0.03 to
0.08. Conditional analysis confirmed the presence of two inde-
pendent signals with Pconditional ¼ 7.9 × 10214 and Pconditional¼
3.7 × 1024 for rs452036 and rs223116, respectively.
For the other five loci, only a single signal of association met
our genome-wide significance threshold, meaning that all other
genome-wide significant SNPs have an r2. 0.1 in HapMap
CEU to the most significant SNP at that locus. For these loci,
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the MAF of the index SNPs ranged from 15 to 50%, effect sizes
ranged between 5.4 and 8.6 ms and Pmeta-gc ranged between
2.1 × 1029 and 1.6 × 10210 (Table 2, Fig. 2C–H). The CD34
locus lost genome-wide significance upon meta-analytic
genomic control but replicates the association reported by
Cho et al. (21). Of these five loci, only the index SNP at 7q22
SLC12A9 shows strong correlation with a non-synonymous
coding SNP. This coding SNP (rs12666989, r2 ¼ 0.88 to
rs314370 in HapMap CEU) results in a Leucine . Valine sub-
stitution at amino acid position 41 in the UfSp1 gene product.
Additionally, an association result that just missed our
genome-wide significance threshold (P ¼ 5.2 × 1028,
Pmeta-gc ¼ 1.1 × 1027) was observed for a non-synonymous
coding SNP in CCDC141 at 2q31. This SNP, rs17362588
(MAF ¼ 0.12, with a 8.3 ms shorter RR interval per A
allele), results in an amino acid substitution at position 360
(Tryptophan . Arginine) of the encoded protein.
Evidence for additional causal loci not reaching
genome-wide significance
We used polygenic modeling methods to quantify the genetic
variance explained and to indicate if loci falling short of genome-
wide significance are likely to harbor additional variants that
influence heart rate. The explained variance of resting heart
rate in RS-II (first extended Rotterdam Study cohort; n ¼
1589) was 0.7% when the score was calculated based on
genome-wide significant signals. Inclusion of 20 independent
variants with P, 1 × 1025 resulted in the maximal proportion
of explained variance of 1.6% (Supplementary Material,
Fig. S2). These 20 variants included signals from the 7 genome-
wide significant loci and signals from an additional 12 loci,
including several loci with genes of potential cardiac relevance
(see Supplementary Material, Table S3, for full list).
DISCUSSION
The application of genome-wide association methods in a
large sample of subjects of European ancestry identified
common variants at multiple loci associated with inter-
individual variation in resting heart rate. Genetic determinants
of heart rate could alter the function of the sinus node (the
dominant pacemaker in the normal heart) either directly
through altered pacemaking activity (23) or indirectly
through sympathetic or parasympathetic inputs to the heart.
We were therefore encouraged to find that genes at some
of the loci identified here are cardiac ion channels or their
regulatory proteins. Besides a direct effect on sinus node
function, effects on cardiac structure—either developmental
or through remodeling—and function could underlie the
observed associations.
The most strongly related locus on chromosome region
6q22 included two independent association signals 8 and
370 kb away from GJA1. The latter finding is in line with a
recent GWAS that described an association between
rs12110693 and pulse rate in an Asian sample (21).
rs9398652 described in the present study is in perfect
linkage disequilibrium (r2 ¼ 1) with rs12110693 in both the
Caucasian and Asian HapMap reference populations and
thus reflects the same signal 370 kb from GJA1. GJA1
encodes Cx43, a connexin family protein and a major com-
ponent of the cardiac gap junction, crucial in electrical coup-
ling of myocytes (24). Mutations in GJA1 cause a Mendelian
inherited hypoplastic left heart syndrome (25). To our knowl-
edge, a role for Cx43 in pacemaker function in the adult sinus
node has not been reported.
The 14q12 MYH6 locus was also associated with resting
heart rate in the RRGEN study. Its gene product, the myosin
heavy chain-6 protein, is a component of the hexameric
myosin protein. Mutations in MYH6 have been related to Men-
delian forms of hypertrophic cardiomyopathy (26), atrial
septal defect (27) and dilated cardiomyopathy (28). The
index SNP was strongly correlated with an amino acid-altering
common variant in MYH6. The association of the coding SNP
with heart rate raises the possibility that it is the causal variant
and MYH6 the causal gene. This finding replicates the result
of Holm et al. (22) who performed a GWAS on heart rate
in an Icelandic population-based sample. We do report a
Table 1. Baseline characteristics of samples included by cohort
Sample
size
Male [n (%)] Age [mean
(SD), years]
Body mass index
[mean (SD), kg/m2]
Heart rate
(SD, bpm)
RR interval
(SD, ms)
SD of
RR-residual
AGES 1651 622 (37.7) 75.9 (5.5) 26.8 (4.4) 68.3 (10.2) 897.1 (131.0) 128.5
ARIC 6308 2855 (45.3) 53.9 (5.6) 26.7 (4.7) 67.3 (9.0) 907.6 (118.2) 116.1
CHS 2544 951 (37.4) 72.2 (5.3) 26.2 (4.4) 65.7 (9.2) 930.1 (123.6) 121.3
ERF 1275 508 (39.8) 47.1 (14.0) 26.5 (4.5) 64.5 (9.2) 948.5 (128.8) 126.9
FHS 7243 3305 (45.6) 40.2 (10.5) 26.1 (5.0) 69.3 (11.1) 888.2 (139.2) 121.8
KORA F3 995 480 (48.2) 60.0 (10.1) 27.3 (4.4) 65.6 (9.7) 933.8 (130.8) 128.1
KORA S4 1398 654 (46.8) 52.8 (8.7) 27.3 (4.4) 66.4 (9.4) 921.1 (125.6) 122.5
MICROS 919 399 (44.4) 44.8 (16.0) 25.6 (4.8) 68.8 (11.7) 897.0 (151.4) 92.0
NESDA 1456 437 (30.0) 39.8 (12.2) 25.1 (4.7) 68.1 (9.6) 898.7 (125.4) 125.1
ORCADES 546 240 (44.0) 52.6 (14.9) 27.6 (4.9) 62.5 (8.1) 975.2 (119.6) 118.5
RS-I 3781 1441 (38.1) 68.5 (8.6) 26.1 (3.6) 71.2 (10.2) 860.6 (126.4) 124.1
RS-II 1589 695 (43.7) 64.8 (7.4) 27.0 (4.0) 70.3 (10.1) 871.1 (123.9) 122.5
SardiNIA 3977 1678 (42.1) 42.9 (17.3) 25.3 (4.7) 64.5 (10.1) 907.4 (130.0) 127.4
SHIP 2582 1260 (48.8) 46.8 (15.7) 26.8 (4.7) 72.1 (11.4) 852.7 (134.4) 133.5
TwinsUK 2727 117 (4.3) 51.7 (12.5) 25.7 (4.4) 67.1 (9.6) 911.5 (126.3) 125.5
SD, standard deviation; RR-residual, residuals are from linear regression models adjusting for age, sex and body mass index.
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novel-independent signal located near MYH7. Future research
is warranted to define the allelic architecture of this locus in
relation to heart rate. Of note, cardiac-specific microRNAs
encoded within intronic regions of MYH6 (miR-208a) and
MYH7 (miR-208b) have regulatory effects on cardiac
conduction (29,30).
The locus on chromosome 12p12 includes several genes,
but without a clear candidate for association with heart rate
in the associated interval. The closest genes are BCAT1,
which encodes a cytosolic form of the branched-chain amino
acid transaminase enzyme that catalyzes transamination of
branched-chain amino acids to their respective alpha-keto
acids essential for cell growth and protein synthesis and
SOX5, a member of the Sox family (31) and of incompletely
understood function. Sox genes play a major role in cell fate
modulation through transcriptional activity but without a
clear cardiac role for SOX5 (32). The variant at 12p12 we
describe here, rs17287293, is a perfect proxy for rs11047543
which was associated with the PR interval (reflecting atrial
depolarization duration and atrioventricular nodal conduction
time) in a GWAS (33), independent of heart rate, suggesting
pleiotropic electrophysiological effects.
The second locus on 6q22 is located near SLC35F1 and
PLN, which encodes phospholamban. This locus is located
.3 Mb away from the loci near GJA1 on 6q22. We have pre-
viously described the common variation at this locus to be
associated with heart rate corrected QT interval (34–36).
The index SNP reported here was in moderate linkage disequi-
librium with two SNPs associated with heart rate-adjusted QT
interval duration [rs11756438 (35), r2 ¼ 0.43 in HapMap
CEU, RR interval P ¼ 6.5 × 1026 and rs11970286 (34),
r2 ¼ 0.58 in HapMap CEU, RR interval P ¼ 2.7 × 1028],
resulting in overlapping signals in independent phenotypes.
In addition to higher heart rate and longer QT interval, this
locus has also been associated with decreased end-diastolic
left ventricular diameter in the EchoGen Study (37). In
humans, the sinoatrial node shows comparable expression of
phospholamban compared with atrial myocytes (23).
However, basal cAMP-mediated, protein kinase A (PKA)-
dependent phosphorylation of phospholamban is elevated in
sinoatrial nodal pacemaker cells compared with other
cardiac cell types (38). Basal PKA-dependent phosphorylation
is obligatory for spontaneous basal pacemaking activity, and
graded changes in the phosphorylation of phospholamban
cause graded changes of the pacemaker cell basal heart rate
(38,39). The location of the top SNP at this locus in an
intron of SLC35F1, which is mainly expressed in the brain
(40), raises the possibility that causal variation influencing
this gene in fact underlies the association at the locus.
However, the observation that heart rate, QT interval and
left ventricular structure are all associated with genetic vari-
ation at this locus makes phospholamban the best candidate
in light of its role in excitation–contraction coupling and
intracellular calcium signaling, critical to action potential
development in both the sinoatrial node and ventricles.
A locus without a clear candidate to explain its strong
association with resting heart rate is located on chromosome
7q22 with the index SNP in SLC12A9 encoding a cation-Cl2
co-transporter-interacting protein. However, this SNP was
strongly correlated with genome-significant SNPs in TRIP6
encoding a thyroid receptor-interacting protein, AChE, which
encodes acetylcholinesterase and a non-synonymous-coding
SNP in UfSp1. This gene encodes an ubiquitin-fold modifier
protease (41,42).
The exact same signal that we report from the FADS1 locus
on 11q12 was previously associated with cholesterol levels
Table 2. Association analysis results for independent index SNPs from loci with P , 5 × 1028 in the meta-analysis
Chr Basepair
position
(kb)
SNP Correlation
with index
SNPa
Function/gene Coded/
non-coded
allele
Allele
frequency
Effective
sample
Effect
estimate
SE Two-sided
P
Two-sided
Pmeta-gc
6q22 122 187 rs9398652 – Intergenic, 400 kb
from GJA1
A/C 0.10 37 050 212.6 1.56 7.73 10216 3.83 10215
6q22 121 790 rs11154022 0.006 Intergenic, 8 kb
from GJA1
A/G 0.33 31 676 5.8 1.05 3.53 1028 7.2 × 1028
14q12 22 935 rs452036 – Intronic MYH6 A/G 0.36 34 640 27.8 1.00 8.13 10215 3.83 10214
14q12 22 931 rs365990 0.96 Non-synonymous
coding MYH6
(Ala-1101-Val)
G/A 0.37 32 627 27.7 1.02 5.43 10214 2.13 10213
14q12 23 046 rs223116 0.08 Intergenic, nearest
to MYH7, NDNG
A/G 0.24 26 899 27.4 1.30 1.13 1028 2.53 1028
12p12 24 662 rs17287293 – Intergenic G/A 0.15 37 988 8.6 1.31 5.73 10211 1.63 10210
6q22 118 680 rs281868 – Intronic SLC35F1 G/A 0.50 32 109 26.3 0.99 1.53 10210 4.33 10210
7q22 100 291 rs314370 – Intronic SLC12A9 C/T 0.19 35 170 27.6 1.21 2.33 10210 6.13 10210
7q22 100 324 rs12666989 0.88 Non-synonymous
coding UfSp1
(Leu-41-Val)
C/T 0.18 35 750 27.0 1.21 9.43 1029 2.13 1028
11q12 61 327 rs174547 – Intronic FADS1 C/T 0.33 34 907 26.2 1.01 8.23 10210 2.13 1029
1q32 206 195 rs2745967 – Intergenic near
CD34
G/A 0.37 34 913 5.4 0.98 3.23 1028 6.6 × 1028
Chromosomal positions and coded alleles are given relative to the forward strand of NCBI build 36. Effect sizes (on the millisecond scale) are shown as beta
estimates from linear regression models for each additional copy of the coded allele. The effective sample size reflects the imputation quality-adjusted sample size.
Final column shows the P-value from inverse variance weighted meta-analyses. Chr, chromosome; SE, standard error. Bold values indicate P, 5 × 1028
aCEU HapMap population linkage disequilibrium r2 values to the index SNP.
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(43–45) and fatty acid metabolism (46,47). The direct product
of the reaction catalyzed by FADS1 is arachidonyl-CoA,
which has been shown to release Ca2+ from the sarcoplasmic
reticulum (48).
The 1q32 CD34/C1orf132 locus has no clear potential mech-
anism through which it is related to heart rate and it loses
genome-wide significance after applying post-meta-analysis
genomic control. However, it is likely to be truly associated
with pulse rate since it was previously identified in a non-
Caucasian sample (21), and our study thus represents a replica-
tion of this finding in a different ethnic group.
The 2q31 CCDC141 locus just missed our genome-wide
significance threshold, but the most significant SNP is a non-
synonymous coding variant within CCDC141, a coiled-coil
domain containing protein of unknown function. Interestingly,
the nearby TTN gene encodes Titin, which is expressed in
cardiac and skeletal myocytes (49) and plays a key role in
muscle assembly, force transmission and maintenance of
resting tension (50).
In additional analysis, we have shown that based on the
results of this GWAS, the explained variance could be
increased to 1.6% with the inclusion of additional signals
with P, 1025. The goal of this analysis was to describe
whether additional variants associated with heart rate are
likely to be present. Although true positives are among these
loci, we cannot discriminate them from the false-positives.
We did observe that the loci contributing to the maximal
explained variance include loci of specific interest. Three
loci that stand out are 3q26 near GNB4, 12p13 near
CACNA1C and 14q11 near PRKD1. GNB4 encodes Gb4
known to influence G-protein-activated inwardly rectifying
K+ channels (GIRK) that play an important role in heartbeat
regulation (51–54) and are activated on binding of acetyl-
choline to the muscarinic M2-receptor present in the sinoatrial
node (23,54). CACNA1C encodes the alpha-1 subunit of the
voltage-dependent calcium channel and is related to Timothy’s
syndrome including, among other traits, prolonged QT inter-
val, high arrhythmia risk and with a single observation of
in utero bradycardia (55). Lastly, the PRKD1 gene product
is relevant for calcium-/calmodulin-dependent kinase affecting
cardiac remodeling and contraction (56). Validation studies in
independent samples have to indicate whether these loci are
truly associated with heart rate.
Strengths and limitations
The large sample derived from several population-based
cohort studies allowed us to identify common variants with
modest effects. In addition, these cohort studies have extensive
data on covariates and disease status that allowed us to harmo-
nize exclusion criteria and phenotype modeling prior to ana-
lyzing the data.
Additional signals may have been missed due to random
sampling variation, restriction to autosomal SNPs, poor cover-
age of certain genomic regions or rare alleles by the genotyping
platforms used or a lack of power to detect even smaller effects.
Lastly, heart rate is a very dynamic trait. Strong environmental
influences such as chronic physical activity or training as well as
variability in the time at rest or posture at the moment of
measurements and other factors, such as anemia or anxiety,
which we have not accounted for, would add noise to the phe-
notype, which would be expected to bias our study toward the
null but not toward the false inference of association.
Conclusion
RRGEN identified nine signals at seven loci at which common
genetic variation is associated with resting heart rate. Six of
these signals at six loci are novel, while the other three
signals replicate previous findings from GWAS. Several of
these loci include genes encoding ion channel regulator pro-
teins with known involvement in heart rate regulation, or pro-
teins with cardiovascular relevant functions and known
associated Mendelian disorders. These variants may impact
clinical care by identifying novel factors that influence patho-
logic heart rate states, are relevant for cardiac structure and
thereby modulate heart rate, or by improving our understand-
ing of the physiologic basis of heart rate regulation.
Figure 1. RR interval association results for 2.5 million imputed autosomal SNPs in 38 991 individuals from 15 cohorts. Results are shown on the 2log10(P)
scale (y-axis). The x-axis depicts chromosomal position. The gray horizontal line corresponds to the genome-wide significance threshold of P ¼ 5 × 1028.
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Figure 2. (A–I) Regional association plots covering 1 Mb surrounding the index SNP. Statistical significance of SNPs is shown on the 2log10(P) scale as a
function of chromosomal position. The primary SNP is annotated by rs number. Correlation of each plotted SNP to the primary SNP is indicated on a color
scale from white (minimal correlation) to red (maximal correlation). Non-synonymous coding SNPs resulting in amino acid changes in the encoded protein
are plotted as blue circles. Estimated recombination rates from HapMap (blue lines) and RefSeq gene annotations (green arrows) are shown.
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MATERIALS AND METHODS
Study participants
The RRGEN sample consisted of subjects from the five parti-
cipating studies in the Cohorts for Heart and Aging Research
in Genomic Epidemiology Consortium (57)—comprised of
the Age, Gene, Environment Susceptibility (AGES) Study,
the Atherosclerosis Risk in Communities (ARIC) Study, the
Cardiovascular Health Study (CHS), the Framingham Heart
Study (FHS) and the Rotterdam Study (RS)—as well as the
Cooperative Health Research in the Region Augsburg
(KORA) study, the SardiNIA study, the Study of Health in
Pomerania (SHIP), TwinsUK, Netherlands Study of
Depression and Anxiety (NESDA) and three population
isolate studies in the European Special Populations Network
(EUROSPAN), the Erasmus Rucphen Family (ERF), the
South Tyrolean Micro-Isolate (MICROS) and the Orkney
Complex Disease Study (ORCADES). For RRGEN, both the
baseline Rotterdam Study (RS-I) and first extended cohort
(RS-II) were used (58,59). KORA subjects in RRGEN were
drawn from the F3 and S4 cohorts.
Individuals were excluded if they were non-Caucasian, had
atrial fibrillation, a second- or third-degree atrioventricular
block, a pacemaker, a diagnosis of prevalent myocardial
infarction or prevalent heart failure, used beta-adrenergic
blocking agents, non-dihydropyridine calcium antagonists or
digoxin, or had a heart rate ,50 (RR interval . 1200 ms)
or .100 bpm (RR interval , 600 ms).
To adhere to STrenghtening the REporting of Genetic
Associations studies (STREGA) statement guidelines (60), we
include an online supplement with additional information
(Supplementary Material). All studies have approval from their
institutional review committee, and the subjects of all cohorts
provided written informed consent. A more detailed description
of cohorts is given in Supplementary Material, Appendix.
RR interval measurement methods
All cohorts recorded 12-lead ECGs from which the RR inter-
val (which equals the inverse heart rate) was measured. For
cohort-specific details on RR interval measurement methods,
please refer to the Supplementary Material, Appendix.
Genotyping and imputation
Affymetrix and Illumina arrays were used for genotyping.
Using genotype information generated on these platforms, all
cohorts imputed genotypes for a common set of 2.5 million
autosomal SNPs based on linkage disequilibrium patterns
observed in HapMap CEU reference samples (Utah residents
of Northern and Western European descent). The genetic trait
analyzed was the imputed allele dosage, a fractional value
between 0 and 2, reflecting the estimated number of allele
copies of an SNP for each subject. A more detailed description
is given in the Supplementary Material, Appendix and Table S1.
Statistical methods
The resting RR interval was adjusted for age, sex and body
mass index. For each SNP, we tested the genotype for associ-
ation with the covariate-adjusted RR interval under an additive
genetic model using linear regression models (Supplementary
Material, Appendix). We then conducted a fixed-effects,
inverse variance weighted meta-analysis using beta estimates
and standard errors from each of the cohorts with applying
genomic control on a per study basis and additionally
post-meta-analysis (Pmeta-gc). Genomic control refers to the
correction made to the test statistics to account for any
inflation of the test statistic distribution, which can result
from unaccounted population substructure or other technical
biases (61,62). We mapped all SNPs to dbSNP build 129,
resulting in a unique set of 2 650 552 autosomal SNPs, after
confirming the consistency of the coded allele across all
studies. Scripts used for this meta-analysis are available
online (http://www.broadinstitute.org/~debakker/meta.html).
Genome-wide significance was defined as P, 5 × 1028,
based on the estimated multiple testing burden for all common
variants in populations of European ancestry (63). To identify
independent signals reaching the genome-wide significance
threshold within a locus, genome-wide association meta-analysis
results were aggregated into bins by index SNP at a linkage dis-
equilibrium r2 threshold of 0.1, such that all results within a
given bin were correlated to the index SNP at r2 ≥ 0.1 but to
any index SNP in other bins at r2, 0.1. Four index SNPs at
two loci were subsequently analyzed in conditional regression
models (n ≤ 33 846) to assess statistical independence.
Finally, we adopted the polygenic regression modeling
approach as recently described by Purcell et al. (64) and
implemented in PLINK (http://pngu.mgh.harvard.edu/~purcell/
plink) to estimate the genetic variance explained by associated
loci at progressively less stringent P-value thresholds within
the RS-II sample. The outcome of this analysis is a P-value
threshold at which the explained variance is maximized. The
list of loci included in the score yielding the maximum explained
variance will include non-genome-wide loci that in aggregate
contribute to the model’s performance and indicate that
additional true-positive signals are likely to be present within
that list. For this analysis, we removed the RS-I and RS-II data
from the discovery meta-analysis to remove the risk of corre-
lation between the discovery and validation sample and overes-
timation of the explained variance. Subsequently, we obtained a
list of independent signals to be included in the model based on
their statistical significance from the meta-analysis without RS-I
or RS-II (PLINK-clump option, r2 ≥0.05, 1 Mb window) (65).
We summarized variation across associated loci (using signifi-
cance thresholds fromP, 5 × 1028 toP, 0.05) into quantitat-
ive scores per individual. The score was then used as a predictor
in a linear regression analysis in the RS-II sample (n ¼ 1589) and
the resulting r2 is reported as the measure for explained variance
for each P-value threshold.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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